naltrexone
naltrexone: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
naltrexone evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could naltrexone → ALKS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Alkermes plc. (ALKS) Treatment of alcohol dependence in patients able to abstain … | Approved |
Clinical Trials (1)
Neurocomputational Mechanisms of Mood Improvement
Primary endpoint: BOLD Responses in the vmPFC-VS circuit
FDA Decisions1 records
Frequently asked questions
Who is developing naltrexone?
naltrexone is being developed by Alkermes plc..
How many clinical trials involve naltrexone?
BioSniper tracks 1 clinical trial involving naltrexone.
What is naltrexone's latest FDA decision?
The most recent tracked FDA decision for naltrexone is Approval for 1 INDICATIONS AND USAGE Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. VIVITROL contains naltrexone, an opioid antagonist, and is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration ( 1.1 ). VIVITROL is indicated for the preve, dated April 13, 2006.